Coagulation Factor VII Activity and R353Q Polymorphism in Coronary Artery Disease.
- Author:
Hyun Kyung KIM
1
;
Kyung Soon SONG
;
Quehn PARK
;
Ju Yon SUNG
;
Young Sook PARK
;
Wonhm SHIM
;
Sun Ha JEE
Author Information
1. Department of Clinical Pathology, College of Medicine, Yonsei University, Seoul, Korea
- Publication Type:Original Article
- Keywords:
Factor VII;
R353Q polymorphism;
Coronary artery disease
- MeSH:
Alleles;
Blood Coagulation Factors*;
Cholesterol;
Coronary Artery Disease*;
Coronary Vessels*;
Factor VII*;
Genotype;
Humans;
Plasma;
Triglycerides
- From:Korean Journal of Clinical Pathology
1999;19(5):486-490
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: High plasma levels of coagulation factor VII (FVII) are associated with a risk of coronary artery disease (CAD). Plasma FVII levels are influenced by environmental and genetic factors. We investigated whether the risk of CAD is associated with R353Q polymorphism and whether this polymorphism is associated with factor VII activity METHODS: We analysed plasma levels of FVII:C and FVII genotype for R353Q polymorphism in 85 CAD patients, 63 healthy controls, and 27 patient controls. And total cholesterol, HDL-cholesterol and triglyceride were measured in the same study populations. RESULTS: There was no difference among CAD patients, healthy controls, and patient controls in plasma levels of FVII:C. Allele Q of the R353Q polymorphism was less frequent in CAD patients (11.8%) than healthy controls (17.5%), although the difference was not statistically significant. Patients with the RQ genotype had a decreased risk of CAD (odds ratio, 0.29). There was no association between R353Q polymorphism and plasma levels of FVII:C. Plasma levels of FVII:C were positively correlated with total cholesterol and triglyceride. CONCLUSIONS: Our findings suggest that R353Q polymorphism may confer significant protection from CAD and that plasma levels of FVII:C may influenced by total cholesterol and triglyceride.
